483 Roundup: FDA Cites Eight Firms for Quality Issues Post author:Sam Post published:May 5, 2020 Post category:Drug GMP Report The FDA found a range of quality lapses during inspections at eight U.S.-based plants. Source: Drug GMP Report You Might Also Like 483 Roundup: FDA Cites Four Drugmakers for Serious Violations July 9, 2019 Expert: Focus on Data Consistency to Streamline Quality, Compliance April 11, 2016 EMA Invites Comments on Water Quality Guideline for Drugmakers December 3, 2018